Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric finerenone add-on study in chronic kidney disease with proteinuria
NL-OMON54048Phase 3Not yet recruiting
- Sponsor
- Bayer
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone plus ACE inhibitor or ARB with Placebo plus ACE inhibitor or ARB (2 arms). Primary endpoint: UPCR response rate. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON54048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54048.